- Home
- CANF vs VYNE Comparison
CANF vs VYNE Comparison
Compare CANF & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- VYNE
- Stock Information
- Founded
- CANF 1994
- VYNE 2003
- Country
- CANF Israel
- VYNE United States
- Employees
- CANF N/A
- VYNE N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- VYNE Health Care
- Exchange
- CANF Nasdaq
- VYNE Nasdaq
- Market Cap
- CANF 9.6M
- VYNE 7.9M
- IPO Year
- CANF N/A
- VYNE 2018
- Fundamental
- Price
- CANF $0.59
- VYNE $0.41
- Analyst Decision
- CANF Strong Buy
- VYNE Buy
- Analyst Count
- CANF 2
- VYNE 2
- Target Price
- CANF $14.50
- VYNE $8.00
- AVG Volume (30 Days)
- CANF 174.9K
- VYNE 2.6M
- Earning Date
- CANF 11-27-2025
- VYNE 11-06-2025
- Dividend Yield
- CANF N/A
- VYNE N/A
- EPS Growth
- CANF N/A
- VYNE N/A
- EPS
- CANF N/A
- VYNE N/A
- Revenue
- CANF $560,000.00
- VYNE $476,000.00
- Revenue This Year
- CANF $461.72
- VYNE N/A
- Revenue Next Year
- CANF N/A
- VYNE N/A
- P/E Ratio
- CANF N/A
- VYNE N/A
- Revenue Growth
- CANF N/A
- VYNE N/A
- 52 Week Low
- CANF $0.59
- VYNE $0.28
- 52 Week High
- CANF $3.12
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- CANF 32.24
- VYNE 57.89
- Support Level
- CANF $0.60
- VYNE $0.32
- Resistance Level
- CANF $0.64
- VYNE $0.35
- Average True Range (ATR)
- CANF 0.03
- VYNE 0.02
- MACD
- CANF 0.00
- VYNE 0.02
- Stochastic Oscillator
- CANF 2.03
- VYNE 92.82
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.